• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

    1/2/24 5:06:50 PM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email
    SC 13D/A 1 d32418dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    The Oncology Institute, Inc.

    (Name of Issuer)

    Common Stock, par value of $0.0001 per share

    (Title of Class of Securities)

    23343Q100

    (CUSIP Number)

    Christopher Kersey

    Manager

    2100 McKinney Ave, Suite 1760

    Dallas, Texas 75201

    Tel: (214) 420-3481

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 28, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on following pages)

     


    Common Stock CUSIP No. 23343Q100

     

      1    

      NAME OF REPORTING PERSON

     

      Havencrest Healthcare Partners, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)          (b)  

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO (see Item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0 shares

         8   

      SHARED VOTING POWER (1)

     

      8,801,823 shares

         9   

      SOLE DISPOSITIVE POWER

     

      0 shares

       10   

      SHARED DISPOSITIVE POWER (1)

     

      8,801,823 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON (1)

     

      8,801,823 shares

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (2)

     

      11.93%

    14  

      TYPE OF REPORTING PERSON

     

      PN

     

    (1)

    Consists of 8,801,823 shares of Common Stock (as defined herein) for which TOI HC I, LLC is the record owner and excludes 3,325,177 Earnout Shares (as defined herein) that may be issued to TOI HC I, LLC pursuant to the Merger Agreement (as defined herein). Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P.

    (2)

    Based on 73,748,979 shares of Common Stock of the Issuer (as defined herein) outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

     

    2


    Common Stock CUSIP No. 23343Q100

     

      1    

      NAME OF REPORTING PERSON

     

      Havencrest Healthcare Partners GP, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)          (b)  

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO (see Item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      80,000 shares

         8   

      SHARED VOTING POWER (1)

     

      8,801,823 shares

         9   

      SOLE DISPOSITIVE POWER

     

      80,000 shares

       10   

      SHARED DISPOSITIVE POWER (1)

     

      8,801,823 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON (1)

     

      8,881,823 shares

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (2)

     

      12.04%

    14  

      TYPE OF REPORTING PERSON

     

      OO (Limited Liability Company)

     

    (1)

    Consists of 8,801,823 shares of Common Stock for which TOI HC I, LLC is the record owner and excludes 3,325,177 Earnout Shares that may be issued to TOI HC I, LLC pursuant to the Merger Agreement. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P.

    (2)

    Based on 73,748,979 shares of Common Stock of the Issuer outstanding as of November 3, 2023.

     

    3


    Common Stock CUSIP No. 23343Q100

     

      1    

      NAME OF REPORTING PERSON

     

      TOI HC I, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)          (b)  

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO (see Item 3)

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware, United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0 shares

         8   

      SHARED VOTING POWER (1)

     

      8,801,823 shares

         9   

      SOLE DISPOSITIVE POWER

     

      0 shares

       10   

      SHARED DISPOSITIVE POWER (1)

     

      8,801,823 shares

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON (1)

     

      8,801,823 shares

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (2)

     

      11.93%

    14  

      TYPE OF REPORTING PERSON

     

      OO (Limited Liability Company)

     

    (1)

    TOI HC I, LLC is the record owner of the shares and this amount excludes 3,325,177 Earnout Shares that may be issued to TOI HC I, LLC pursuant to the Merger Agreement.

    (2)

    Based on 73,748,979 shares of Common Stock of the Issuer outstanding as of November 3, 2023.

     

    4


    Explanatory Note

    The following constitutes Amendment No. 4 (“Amendment No. 4”) to the Schedule 13D filed by the undersigned with the Securities and Exchange Commission (the “SEC”) on November 22, 2021 (the “Original Schedule 13D”). This Amendment No. 4 amends the Original Schedule 13D as specifically set forth herein.

    Item 2. Identity and Background.

    Paragraph (a) of Item 2 is hereby amended and restated as follows:

    (a) This Amendment No. 4 is being jointly filed by Havencrest Healthcare Partners, L.P., Havencrest Healthcare Partners GP, LLC, and TOI HC I, LLC (each a “Reporting Person” and collectively, the “Reporting Persons”). The name, residence, or principal business address, citizenship, and present principal occupation of each officer or manager of each Reporting Person, as applicable (each, a “Listed Person”), is listed on the updated Schedule I attached hereto.

    The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Act”) was filed as Exhibit 1.1 to the Original Schedule 13D. Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person.

    Item 5. Interest in Securities of the Issuer.

    Paragraphs (a) and (c) of Item 5 are hereby amended and restated as follows:

    (a) Based on the 73,748,979 shares of the Issuer’s Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 8, 2023, the shares of Common Stock held by the Reporting Persons constitute 12.04% of the outstanding shares of Common Stock of the Issuer.

    Each Reporting Person disclaims beneficial ownership of the reported Common Stock except to the extent of such Reporting Person’s pecuniary interest therein, and this statement shall not be deemed an admission that such Reporting Person is the beneficial owner of the reported Common Stock for the purposes of Section 13(d) of the Act or any other purpose.

    The shares of the Issuer’s Common Stock reported in this Item 5 do not include the Earnout Shares described in Item 3 above.

    (c) The information contained in Item 4 is incorporated by reference herein. Except as set forth below or as disclosed herein, none of the Reporting Persons, or to the Reporting Persons’ knowledge, the persons set forth on Schedule I of this Amendment No. 4 has effected transactions in the Common Stock in the past 60 days.

    On December 28, 2023, TOI HC I, LLC distributed an aggregate of 4,561,050 shares of the Issuer’s Common Stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the “TOI HC I Distribution”).

     

    5


    Also on December 28, 2023, following the TOI HC I Distribution, Havencrest Healthcare Partners GP, LLC, on behalf of Havencrest Healthcare Partners, L.P., made a further pro-rata in-kind distribution of the 3,999,998 shares Havencrest Healthcare Partners, L.P. received in the TOI HC I Distribution to Havencrest Healthcare Partners, L.P.’s limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P.

    Item 7. Material to be Filed as Exhibits.

    Item 7 of the Original Schedule 13D is hereby amended to add the following exhibit:

     

    Exhibit 2.5    Power of Attorney (incorporated herein by reference to Exhibit 24.1 to the Reporting Person’s Form 4, filed with the Securities and Exchange Commission on January 2, 2024).

     

    6


    SCHEDULE I

    Havencrest Healthcare Partners, L.P.

    The business and operations of Havencrest Healthcare Partners, L.P. are managed by its general partner, Havencrest Healthcare Partners GP, LLC, as set forth below.

    Havencrest Healthcare Partners GP, LLC

    The name, function, citizenship, and present principal occupation or employment for the officers of Havencrest Healthcare Partners GP, LLC are set forth below. Unless otherwise indicated below, the business address of each officer listed below is 2100 McKinney Avenue, Suite 1760, Dallas, TX 75201.

     

    Name

      

    Position with Reporting
    Person

      

    Principal Occupation/Business

      

    Citizenship

      

    No. Shares Held

    Christopher W. Kersey    Manager and President    Founding Managing Partner of Havencrest Capital Management    United States    0
    Randy Chappel    Manager    Managing Director, Hersh Family Investments    United States    0
    Tom White    Manager    Vice President and Controller of BEPCO, L.P.    United States    0
    Matthew Shofner    Vice President, Secretary and Treasurer    Partner of Havencrest Capital Management    United States    0

    TOI HC I, LLC

    The name, function, citizenship, and present principal occupation or employment for the managers of TOI HC I, LLC are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite the individual’s name refers to employment with Havencrest Healthcare Partners, L.P. and (ii) the business address of each manager listed below is 2100 McKinney Avenue, Suite 1760, Dallas, TX 75201.

     

    Name

      

    Position with Reporting
    Person

      

    Principal Occupation/Business

      

    Citizenship

      

    No. Shares Held

    Christopher W. Kersey    Manager    Founding Managing Partner of Havencrest Capital Management    United States    0
    Matthew Shofner    Manager    Partner of Havencrest Capital Management    United States    0
    Matt Cline    Manager    Vice President of Havencrest Capital Management    United States    0

     

    7


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    January 2, 2024     HAVENCREST HEALTHCARE PARTNERS, L.P.
        By: Havencrest Healthcare Partners GP, LLC, its general partner
        By:  

    /s/ Matthew Shofner

        Name:   Matthew Shofner
        Title:   Vice President, Treasurer and Secretary
        HAVENCREST HEALTHCARE PARTNERS, GP, LLC
        By:  

    /s/ Matthew Shofner

        Name:   Matthew Shofner
        Title:   Vice President, Treasurer and Secretary
        TOI HC I, LLC
        By:  

    /s/ Matthew Shofner

        Name:   Matthew Shofner
        Title:   Manager

     

    8

    Get the next $TOI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    11/25/2025$5.00Buy
    Needham
    7/23/2025$8.00Outperform
    Noble Capital Markets
    7/16/2025$6.00Buy
    B. Riley Securities
    5/15/2025$7.00Buy
    BTIG Research
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Carter Robert Ross disposed of $895 worth of shares (244 units at $3.67), decreasing direct ownership by 0.10% to 235,125 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    1/6/26 4:30:02 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Carter Robert Ross sold $879 worth of shares (247 units at $3.56), decreasing direct ownership by 0.10% to 235,122 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    1/5/26 5:04:59 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Hively Brad sold $50,291 worth of shares (13,333 units at $3.77), decreasing direct ownership by 2% to 683,721 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    12/16/25 4:30:05 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on The Oncology Institute with a new price target

    Needham initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $5.00

    11/25/25 8:00:05 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    B. Riley Securities initiated coverage on The Oncology Institute with a new price target

    B. Riley Securities initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $6.00

    7/16/25 7:58:29 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care

    DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates ("USNA" or the "Company"), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (

    1/9/26 4:45:26 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Leadership Promotions

    Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. These promotions reinforce TOI's continued focus on leading the way in value-based cancer care through further development of our technology-enabled care delivery platform as well as strengthening our mission-oriented culture supported by strong leadership. Rakesh Panda has more than 25 years of experience across IT, digital transformation, cybersecurity, and enterprise software develo

    1/9/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    4/28/25 7:20:14 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:50:27 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:48:39 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    The Oncology Institute Announces Resignation of Board Member Gabe Ling

    CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. "On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute's development," said Anne McGeorge, Chairman of the Board. "We appreciate the contributions he made throughout his time on the Board and the valua

    12/1/25 8:30:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Names Kristin England as Chief Administrative Officer

    CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI's expanding national footprint. England brings over two decades of leadership experience in healthcare management and operations, most recently serving as a senior executive within McKesson's US Oncology Network. There, she led high-performing teams focus

    7/14/25 4:05:25 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    8/20/24 8:20:55 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    1/2/24 5:06:50 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

    SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

    7/10/23 10:20:11 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

    CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended September 30, 2025 and updated its full year 2025 guidance. Recent Operational Highlights Fee-for-service revenue growth of 13% over Q3 2024, driven by continued organic growth performance in Florida and Oregon.Retail Pharmacy and Dispensary set fill records, contributing $75.9 million in revenue and $12.8 million in gross profit in Q3. Signed several new in-network MSO providers in the Florida market and opened our new TOI pharmacy

    11/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Third Quarter 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI),  a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 1

    10/22/25 4:47:31 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

    CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025. Daniel Virnich, CEO of TOI, commented, "We delivered another strong quarter with over 20% year-over-year revenue growth. This was driven by exceptional performance in our pharmacy business, which grew over 40% year-over-year, as well as the addition of over 50,000 new capitated lives to our value-based business. We are also in the process of expanding our partnership into new geographic regions of Florida with a major

    8/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    SEC Filings

    View All

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    1/7/26 5:02:33 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    12/1/25 4:30:53 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by The Oncology Institute Inc.

    SCHEDULE 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    11/20/25 4:01:02 PM ET
    $TOI
    Medical/Nursing Services
    Health Care